MQI-181 / Mabqi - LARVOL DELTA

Tumor-specific anti-CD30 ADC limits sCD30 sink effects and improves in-vivo efficacy compared to brentuximab vedotin (ESMO-TAT 2026) - "Funding: Mabqi. Mechanistic investigation of our lead 18D03 describes a pH-sensitive antibody that binds CD30 on a unique epitope. In ADC format, MQI-181 demonstrated a strong anti-tumoral efficacy even in the presence of sCD30, indicating that its pH-sensitive binding prevents sCD30 from acting as a durable sink. MQI-181 appears to be a promising drug candidate to be developed in various CD30-positive cancers."

ADC • Preclinical • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Next-generation tumor-specific anti-CD30 ADC as a new therapy in hemato-oncology (ASH 2025) - "Tournilhac, Blood Advances2025) demonstrated that high circulating sCD30 levels were associated with poor prognosis in patientstreated with Brentuximab Vedotin (BV)...MQI-181 is a next-generation anti-CD30 therapy with high clinical potential, able tospecifically target the tumor site while avoiding its capture by circulating CD30. In vivo, MQI-181demonstrated complete tumor regression in a preclinical lymphoma cancer model and superiority overBV in the presence of soluble CD30. The Phase I trial is now under planification."

Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology